Loading animation
  • Home
  • About us View About us's child pages
    • Who we are
    • Our business model
    • Our strategy
    • Board of Directors
  • What we do View What we do's child pages
    • Our technology
    • Our product development pipeline
    • MED3000 View MED3000's child pages
      • MED3000 Overview
      • MED3000 Clinical Programme
      • MED3000 Commercial potential
    • TPR100 View TPR100's child pages
      • TPR100 Clinical Data
      • TPR100 Commercial potential
    • Other products View Other products's child pages
      • TIB200
      • CBD100
      • CSD500
    • Products FAQ's View Products FAQ's's child pages
      • DermaSys® FAQs
      • MED3000 FAQs
      • MED2005 FAQs
      • TPR100 FAQs
      • CBD100 FAQs
  • Investor centre View Investor centre's child pages
    • Share price chart
    • Corporate documentation
    • Videos and webcasts View Videos and webcasts's child pages
      • Videos
      • Webcasts
    • RNS
    • Alert service
    • Shareholder centre View Shareholder centre's child pages
      • Investor contacts and advisors
      • Shareholder information
      • Financial calendar
      • Investor FAQs
      • Analyst Research View Analyst Research's child pages
        • 2020
        • 2019
    • Corporate Governance
    • AIM rule 26
  • Media View Media's child pages
    • News
    • Event calendar
    • RNS
    • Videos
    • Alert service
  • Contact us

Please use the arrows to navigate to the sub pages

  • About us View About us's child pages

    About us

    Futura Medical is a pharmaceutical company developing a portfolio of innovative products based on our proprietary, transdermal DermaSys®  technology.

    Explore this section
    • Who we are
    • Our business model
    • Our strategy
    • Board of Directors
  • What we do View What we do's child pages

    What we do

    Futura Medical is developing a portfolio of innovative products for two large markets, sexual health and pain.

    Explore this section
    • Our technology
    • Our product development pipeline
    • MED3000 View MED3000's child pages

      MED3000

      • MED3000 Overview
      • MED3000 Clinical Programme
      • MED3000 Commercial potential
    • TPR100 View TPR100's child pages

      TPR100

      • TPR100 Clinical Data
      • TPR100 Commercial potential
    • Other products View Other products's child pages

      Other products

      • TIB200
      • CBD100
      • CSD500
    • Products FAQ's View Products FAQ's's child pages

      Products FAQ's

      • DermaSys® FAQs
      • MED3000 FAQs
      • MED2005 FAQs
      • TPR100 FAQs
      • CBD100 FAQs
  • Investor centre View Investor centre's child pages

    Investor centre

    Futura has a proven track record in delivery and completion of Research & Development projects up to value inflection points at which they are suitable for commercialisation partners.

    WEBCASTS

    Explore this section
    • Share price chart
    • Corporate documentation
    • Videos and webcasts View Videos and webcasts's child pages

      Videos and webcasts

      • Videos
      • Webcasts
    • RNS
    • Alert service
    • Shareholder centre View Shareholder centre's child pages

      Shareholder centre

      • Investor contacts and advisors
      • Shareholder information
      • Financial calendar
      • Investor FAQs
      • Analyst Research View Analyst Research's child pages
        • 2020
        • 2019
    • Corporate Governance
    • AIM rule 26
  • Media View Media's child pages

    Media

    This section contains the latest RNS, news and videos.

    Explore this section
    • News
    • Event calendar
    • RNS
    • Videos
    • Alert service
  • Contact us
  • About us View About us's child pages
    • Who we are
    • Our business model
    • Our strategy
    • Board of Directors
  • What we do View What we do's child pages
    • Our technology
    • Our product development pipeline
    • MED3000 View MED3000's child pages
      • MED3000 Overview
      • MED3000 Clinical Programme
      • MED3000 Commercial potential
    • TPR100 View TPR100's child pages
      • TPR100 Clinical Data
      • TPR100 Commercial potential
    • Other products View Other products's child pages
      • TIB200
      • CBD100
      • CSD500
    • Products FAQ's View Products FAQ's's child pages
      • DermaSys® FAQs
      • MED3000 FAQs
      • MED2005 FAQs
      • TPR100 FAQs
      • CBD100 FAQs
  • Investor centre View Investor centre's child pages
    • Share price chart
    • Corporate documentation
    • Videos and webcasts View Videos and webcasts's child pages
      • Videos
      • Webcasts
    • RNS
    • Alert service
    • Shareholder centre View Shareholder centre's child pages
      • Investor contacts and advisors
      • Shareholder information
      • Financial calendar
      • Investor FAQs
      • Analyst Research View Analyst Research's child pages
        • 2020
        • 2019
    • Corporate Governance
    • AIM rule 26
  • Media View Media's child pages
    • News
    • Event calendar
    • RNS
    • Videos
    • Alert service
  • Contact us
    Male back pain

    TPR100 FAQs

    • Home
    • What we do
    • Products FAQ's
    • TPR100 FAQs

    • When do you expect Thornton & Ross to obtain regulatory approval within the UK?

      In February 2019, the UK Medicines and Healthcare products Regulatory Agency (MHRA) responded to Thornton & Ross’s marketing authorisation application filed in July 2018, raising a number of questions requiring additional laboratory work specifically around the permeation characteristics of TPR100 to be conducted. 

      As mentioned in the Interim Results for the Six Months ended 30 June 2020 (September 2020 RNS) post period events:

      • Additional laboratory work required by the UK Medicines and Healthcare products Regulatory Agency ("MHRA") to support the UK submission made by partner Thornton & Ross (a subsidiary of STADA AG) has been completed.
      • In conjunction with its commercial partner, Futura is seeking a scientific advisory meeting with the MHRA before year end to review data and confirm the exact pathway for approval.
    • What formulation of DermaSys® is used for the TPR100 product? How does this differ from MED3000?

      Our transdermal technology DermaSys® is tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action offering improvements over existing products creating novel indications with compelling commercial potential. This means that our products are highly differentiated in their markets whilst avoiding the risks normally associated with the development of new molecules.

      The rapid skin permeation rate offered by our transdermal delivery system, DermaSys®, is ideally suited for targeted topical pain relief. Rapid, targeted and effective skin permeation offers potential benefits in pain management including: improved onset of action, duration and degree of pain relief.

      TPR100 does not require a combination of volatile solvent components to stimulate nerve sensors.  It is designed to provide a sustained mode of action suitable for the treatment of pain and is formulated with this objective in mind.

    • What is the IP position of this specific formulation?

      TPR100's current patent protection runs until February 2028 in the USA and Europe.

    You may also be interested in

    Our technology
    TPR100 Commercial potential
    MED3000
    Futura Medical logo

    ©2021 Futura Medical

    • Sitemap
    • Contact us
    • Accessibility
    • Terms of use
    • Privacy & cookies policies

    Designed and developed by
    jonesandpalmer.co.uk